Scholarlink

<p>The present study investigated the distinct metabolic profiles of two primary traditional Chinese medicine (TCM) syndromes in patients with cholelithiasis—liver Qi stagnation (LQS) and liver-gallbladder damp-heat (LGDH). By integrating untargeted and targeted metabolomics, we aimed to identify objective serum and urine biomarkers for syndrome differentiation and to elucidate their underlying biological basis. In total, 91 participants, comprising 33 healthy controls (HCs), 30 cholelithiasis patients with LQS syndrome, and 28 cholelithiasis patients with LGDH syndrome, were enrolled. Untargeted analysis of serum and urine samples quantified 602 and 636 metabolites, respectively. To strengthen the robustness of the dataset, complementary targeted metabolomics was conducted as an orthogonal validation step, providing reliable quantification for 210 serum and 204 urinary. The present findings provide molecular insights into the TCM principle of syndrome differentiation (Bian Zheng Lun Zhi). The identified biomarker panel may offer a basis for developing objective tools for the stratification of cholelithiasis syndromes and may support future efforts towards personalized therapeutic strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Serum and Urine Metabolomics Dataset of TCM Syndromes in Cholelithiasis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月6日

查看全文
  • Anliang Huang,
  • Jifeng Liu,
  • Yunshu Zhang,
  • Saiyu Shi,
  • Yifeng Hao,
  • Dong Shang,
  • Qingkai Zhang,
  • Shurong Ma,
  • Peiyuan Yin

摘要

The present study investigated the distinct metabolic profiles of two primary traditional Chinese medicine (TCM) syndromes in patients with cholelithiasis—liver Qi stagnation (LQS) and liver-gallbladder damp-heat (LGDH). By integrating untargeted and targeted metabolomics, we aimed to identify objective serum and urine biomarkers for syndrome differentiation and to elucidate their underlying biological basis. In total, 91 participants, comprising 33 healthy controls (HCs), 30 cholelithiasis patients with LQS syndrome, and 28 cholelithiasis patients with LGDH syndrome, were enrolled. Untargeted analysis of serum and urine samples quantified 602 and 636 metabolites, respectively. To strengthen the robustness of the dataset, complementary targeted metabolomics was conducted as an orthogonal validation step, providing reliable quantification for 210 serum and 204 urinary. The present findings provide molecular insights into the TCM principle of syndrome differentiation (Bian Zheng Lun Zhi). The identified biomarker panel may offer a basis for developing objective tools for the stratification of cholelithiasis syndromes and may support future efforts towards personalized therapeutic strategies.